Application of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after PCI for acute myocardial infarction

doi:10.3760/cma.j.issn.1007-1245.2024.20.018

Abstract

Abstract:

Objective　To investigate the application value of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Methods　A total of 194 AMI patients who underwent PCI at Xi'an Hospital of Traditional Chinese Medicine from November 2021 to October 2023 were selected for the study objects. They were randomly divided into a control group (97 cases) and a combined group (97 cases) using computer coding method. In the control group, there were 56 males and 41 females, aged 36-74 (55.83±8.42) years, 1-6 (3.49±0.63) h after PCI. There were 53 males and 44 females in the combined group, aged 36-75 (55.87±8.46) years, 1-6 (3.53±0.58) h after PCI . The control group was treated with Sacubitril/Valsartan sodium tablets combined with conventional treatment, while the combined group additionally received Tongxinluo capsules. After 8 weeks of treatment, they were followed up for 6 months. The blood flow grading of thrombolysis in myocardial infarction (TIMI), cardiac function [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF)] and levels of inflammatory factors [hypersensitive C-reactive protein (hs-CRP) and interleukin (IL) -6] before and after treatment, and incidence of major adverse cardiovascular events (MACE) during follow-up were compared between the two groups. Independent sample t test, paired t test, rank sum test, and χ² test were used. Results　After treatment, the TIMI blood flow grading in the combined group was better than that in the control group (P<0.05). After treatment, the LVESD [(32.44±4.29) mm] and LVEDD [(40.35±4.92) mm] in the combined group were lower than those in the control group [(38.64±4.82) mm and (47.82±5.73) mm], and the LVEF [(65.83±5.78)%] was higher than that in the control group [(58.36±5.36)%] (all P<0.05); the levels of hs-CRP [(3.11±1.28) mg/L] and IL-6 [(12.43±3.27) ng/L] in the combined group were lower than those in the control group [(6.84±1.93) mg/L and (15.68±3.94) ng/L] (both P<0.05). During follow-up, the total incidence of MACE in the combined group [12.37% (12/97)] was lower than that in the control group [26.80% (26/97)] (P<0.05). Conclusion　The combination of Sacubitril/Valsartan sodium tablets and Tongxinluo capsules can improve the cardiac function and the levels of inflammatory factors in AMI patients after PCI, and reduce the total incidence of MACE.

Key words:

Acute myocardial infarction, Percutaneous coronary intervention, Sacubitril/Valsartan sodium tablets, Tongxinluo capsules

摘要：

目的　探讨沙库巴曲缬沙坦钠片联合通心络胶囊在急性心肌梗死（AMI）患者经皮冠状动脉介入（PCI）术后中的应用价值。方法　选取2021年11月至2023年10月在西安市中医医院行PCI治疗的194例AMI患者作为研究对象。通过电脑编码，将患者随机分为对照组（97例）和联合组（97例）。对照组男56例，女41例；年龄36～74（55.83±8.42）岁；PCI术后1～6（3.49±0.63）h。联合组男53例，女44例；年龄36～75（55.87±8.46）岁；PCI术后1～6（3.53±0.58）h。对照组采用常规治疗联合沙库巴曲缬沙坦钠片口服治疗，联合组在对照组基础上采用通心络胶囊口服治疗。两组均治疗8周，治疗后随访6个月。比较两组治疗前后心肌梗死溶栓试验（TIMI）血流分级、心功能［左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、左心室射血分数（LVEF）］和炎症因子水平［超敏C反应蛋白（hs-CRP）和白细胞介素（IL）-6］，随访期间主要不良心血管事件（MACE）发生情况。采用独立样本t检验、配对t检验、秩和检验和χ²检验。结果　治疗后，联合组TIMI血流分级优于对照组（P<0.05）；联合组LVESD［（32.44±4.29）mm］、LVEDD［（40.35±4.92）mm］均低于对照组［（38.64±4.82）mm、（47.82±5.73）mm］，LVEF［（65.83±5.78）%］高于对照组［（58.36±5.36）%］（均P<0.05）；联合组hs-CRP［（3.11±1.28）mg/L］、IL-6［（12.43±3.27）ng/L］水平均低于对照组［（6.84±1.93）mg/L、（15.68±3.94）ng/L］（均P<0.05）。随访期间，联合组MACE总发生率［12.37%（12/97）］低于对照组［26.80%（26/97）］（P<0.05）。结论　沙库巴曲缬沙坦钠片与通心络胶囊联合使用可改善AMI患者PCI术后心功能和炎症因子水平，降低MACE总发生率。

关键词:

急性心肌梗死, 经皮冠状动脉介入, 沙库巴曲缬沙坦钠片, 通心络胶囊

Li Ping, Wang Xin, Li Zhen.

Application of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after PCI for acute myocardial infarction [J]. International Medicine and Health Guidance News, 2024, 30(20): 3438-3442.

李萍王新李臻.

沙库巴曲缬沙坦钠片联合通心络胶囊在AMI患者PCI术后中的应用 [J]. 国际医药卫生导报, 2024, 30(20): 3438-3442.

References

[1] Gulati R, Behfar A, Narula J, et al. Acute myocardial infarction in young individuals[J]. Mayo Clin Proc, 2020, 95(1):136-156. DOI: 10.1016/j.mayocp.2019.05.001.
[2] 王滋,仇盛蕾,尚菊菊.基于真实世界数据挖掘的急性心肌梗死患者临床特征研究[J].时珍国医国药,2023,34(11):2706-2709.DOI:10.3969/j.issn.1008-0805.2023.11.34.
[3] Krittanawong C, Khawaja M, Tamis-Holland JE, et al. Acute myocardial infarction: etiologies and Mimickers in young patients[J]. J Am Heart Assoc, 2023, 12(18):e029971. DOI: 10.1161/JAHA.123.029971.
[4] 普珍,尼玛,沈爱东,等.冠状动脉造影正常的ST段抬高胸痛患者病因分析[J].临床和实验医学杂志,2020,19(19):2082-2085.DOI:10.3969/j.issn.1671-4695.2020.19.018.
[5] 孙鹊云,宋莹.经皮冠状动脉介入治疗围手术期心肌损伤/心肌梗死研究进展[J].中国分子心脏病学杂志,2022,22(6):5073-5079.DOI:10.16563/j.cnki.1671-6272.2022.12.014.
[6] 桂沛君,吴坚,史昊楠,等.急性心肌梗死患者经皮冠状动脉介入治疗后急性期心脏康复参与现状及其影响因素研究[J].实用心脑肺血管病杂志,2022,30(8):34-37,43.DOI:10.12114/j.issn.1008-5971.2022.00.169.
[7] 苏鹏,杨秀丽.达格列净联合诺欣妥对非糖尿病急性心肌梗死患者急诊PCI术后心力衰竭的疗效观察[J].中国循证心血管医学杂志,2023,15(8):970-973.DOI:10.3969/j.issn.1674-4055.2023.08.17.
[8] 苏扬,崔书克,陈爽,等.通心络胶囊治疗脑梗死恢复期有效性及安全性的Meta分析[J].中西医结合心脑血管病杂志,2023,21(18):3329-3335.DOI:10.12102/j.issn.1672-1349. 2023.18.007.
[9] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会.急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404.DOI:10.3760/cma.j.issn.1671-0282.2016.04.002.
[10] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.DOI:10.3760/cma.j.issn.0253-3758.2017.05.003.
[11] 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.DOI:10.3760/cma.j.issn.0253-3758.2019.10.003.
[12] 高玉龙,龚晓刚,陶英,等.心肌梗死溶栓试验危险评分与ST段抬高型心肌梗死患者直接冠状动脉介入术后心肌组织灌注的关系分析[J].中国医药,2019,14(10):1470-1473.DOI:10.3760/j.issn.1673-4777.2019.10.008.
[13] 冯世华,朱国斌,王瑾.45岁以下人群急性心肌梗死危险因素的研究进展[J].中西医结合心脑血管病杂志,2023,21(24):4554-4557.DOI:10.12102/j.issn.1672-1349.2023. 24.014.
[14] 高洁,娜迪拉,方志敏.miRNA在急性心肌梗死诊断、治疗及预后中的研究进展[J].实用临床医药杂志,2022,26(1):139-142.DOI:10.7619/jcmp.20212567.
[15] 王海燕,姜卫星,田丽,等.沙库巴曲缬沙坦对急性前壁ST段抬高型心肌梗死PCI术后心力衰竭患者心功能的影响[J].河北医科大学学报,2020,41(3):254-258,267.DOI:10.3969/j.issn.1007-3205.2020.03.002.
[16] 徐颖,裘淼涵,祁子钊,等.OPT-CAD评分对行直接PCI术后急性心肌梗死患者缺血事件风险的预测研究[J].中国现代医学杂志,2023,33(15):87-92.DOI:10.3969/j.issn.1005- 8982.2023.15.014.
[17] 陆益,胡伟,尹桂芝,等.诺欣妥对射血分数降低的心力衰竭患者血管内皮损伤及生活质量的影响[J].现代生物医学进展,2020,20(10):1864-1867.DOI:10.13241/j.cnki.pmb.2020.10.014.
[18] 王根柱,孙强,王小营,等.基于CYP2C19基因多态性选择抗血小板药物对急性冠状动脉综合征或经皮冠状动脉介入治疗患者主要心血管事件和出血风险影响的Meta分析[J].中国药师,2022,25(9):1578-1584.DOI:10.19962/j.cnki.issn1008-049X.2022.09.015.
[19] 李鸿海,孙小芳.通心络胶囊对经皮冠状动脉介入治疗术后患者心功能改善及心肌酶谱表达的影响[J].中国医师进修杂志,2022,45(4):348-351.DOI:10.3760/cma.j.cn115455- 20201111-01560.
[20] 张磊,丁辉.通心络胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的疗效及对患者心功能和炎症因子的影响[J].海南医学,2021,32(24):3162-3165.DOI:10.3969/j.issn.1003-6350.2021.24.010.
[21] 葛腾,李舒钰,宁博,等.芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭有效性及安全性的Meta分析[J].中西医结合心脑血管病杂志,2023,21(14):2531-2542.DOI:10.12102/j.issn.1672-1349.2023.14.003.
[22] 赵刚,张虹.沙库巴曲缬沙坦应用于心血管疾病研究进展[J].安徽医药,2020,24(7):1273-1277.DOI:10.3969/j.issn.1009-6469.2020.07.001.
[23] 叶素伶,李杰,王莉莉.沙库巴曲/缬沙坦在甲亢性心脏病的防治作用[J].中国心血管病研究,2023,21(10):909-914.DOI:10.3969/j.issn.1672-5301.2023.10.008.
[24] 梁凤楚,钟龙和,吴爵非.超声辅助溶栓治疗急性ST段抬高型心肌梗死的研究进展[J].临床心血管病杂志,2021,37(7):595-599.DOI:10.13201/j.issn.1001-1439.2021.07.002.
[25] 郭流漓,杨昊霖,杨志华,等.通心络胶囊治疗冠状动脉微血管病的临床疗效及其作用机制研究进展[J].现代药物与临床,2024,39(2):530-535.DOI:10.7501/j.issn.1674-5515. 2024.02.044.
[26] 秘红英,宋红霞,李雅文,等.通心络胶囊治疗心肌梗死后心力衰竭的研究进展[J].天津中医药,2020,37(9):1076-1080.DOI:10.11656/j.issn.1672-1519.2020.09.26.
[27] Zhu GX, Zuo JL, Xu L, et al. Ginsenosides in vascular remodeling: cellular and molecular mechanisms of their therapeutic action[J]. Pharmacol Res, 2021, 169:105647. DOI: 10.1016/j.phrs.2021.105647.
[28] Han JY, Li Q, Ma ZZ, et al. Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion[J]. Pharmacol Ther, 2017, 177:146-173. DOI: 10.1016/j.pharmthera.2017.03.005.
[29] 周文文,刘晖,徐志佳,等.酸枣仁不同极性部位成分含量与抗氧化活性及其相关性分析[J].食品工业科技,2023,44(16):288-296.DOI:10.13386/j.issn1002-0306. 2022090054.
[30] 王文生·王月,陈悦,贾红娥,等.冰片增强依达拉奉对脑缺血再灌注损伤大鼠抗氧化作用研究[J].吉林中医药,2021,41(11):1497-1501.DOI:10.13463/j.cnki.jlzyy.2021. 11.025.
[31] Ma J, Qiao L, Meng L, et al. Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip[J]. Biomed Pharmacother, 2019, 113:108767. DOI: 10.1016/j.biopha.2019.108767.
[32] Zhang M, Liu Y, Xu M, et al. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): a multicenter randomized double-blind parallel-group placebo-controlled study[J]. Sci Rep, 2019, 9(1):4545. DOI: 10.1038/s41598-019-41118-z.